Trial · NCT03468855
Outcomes31
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 31
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline to Week 24 | Baseline to 24 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline Compared to Week 48 | Baseline to 48 Weeks | Subjects completing 24 weeks of treatment have the option to extend treatment for an additional 24 weeks. Subjects not wishing to continue treatment can withdraw consent. | score on a scale | MEAN |
| SECONDARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline Compared to Week 4 | Baseline to 4 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline Compared to Week 8 | Baseline to 8 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline Compared to Week 12 | Baseline to 12 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline Compared to Week 16 | Baseline to 16 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Visit 2 Compared to Week 20 | Baseline to 20 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline Compared to Week 32 | Baseline to 32 Weeks | Subjects completing 24 weeks of treatment have the option to extend treatment for an additional 24 weeks. Subjects not wishing to continue treatment can withdraw consent. | score on a scale | MEAN |
| SECONDARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline Compared to Week 40 | Baseline to 40 Weeks | Subjects completing 24 weeks of treatment have the option to extend treatment for an additional 24 weeks. Subjects not wishing to continue treatment can withdraw consent. | score on a scale | MEAN |
| SECONDARY | Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline Compared to Post-treatment Week 52 | Baseline to 52 Weeks | Subjects completing 24 weeks of treatment have the option to extend treatment for an additional 24 weeks. Subjects not wishing to continue treatment can withdraw consent. | score on a scale | MEAN |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Week 4 | Baseline to 4 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Week 8 | Baseline to 8 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Week 12 | Baseline to 12 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Week 16 | Week 16 | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Week 20 | Baseline to 20 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Week 24 | Baseline to 24 Weeks | score on a scale | MEAN | |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Week 32 | Baseline to 32 Weeks | Subjects completing 24 weeks of treatment have the option to extend treatment for an additional 24 weeks. Subjects not wishing to continue treatment can withdraw consent. | score on a scale | MEAN |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Week 40 | Baseline to 40 Weeks | Subjects completing 24 weeks of treatment have the option to extend treatment for an additional 24 weeks. Subjects not wishing to continue treatment can withdraw consent. | score on a scale | MEAN |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Week 48 | Baseline to 48 Weeks | Subjects completing 24 weeks of treatment have the option to extend treatment for an additional 24 weeks. Subjects not wishing to continue treatment can withdraw consent. | score on a scale | MEAN |
| SECONDARY | Mean Change From Baseline in the Facial Assessment of the Vitiligo Area Scoring Index (F-VASI) Compared to Post-treatment Week 52 | Baseline to 52 Weeks | Subjects completing 24 weeks of treatment have the option to extend treatment for an additional 24 weeks. Subjects not wishing to continue treatment can withdraw consent. | score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03468855/outcomes